# A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07160725/  
OnCo record `nct07160725` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.

## Summary

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07160725 by Bristol-Myers Squibb, with 540 participants planned, started 2025-10-15 and due to reach its primary completion in 2028-07-31. Interventions recorded: BMS-986517 and Pumitamig.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07160725
- Phase: 1/2
- Setting: A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
- Sponsor: Bristol-Myers Squibb
- Enrolled: 540

## Sources

- ClinicalTrials.gov NCT07160725: https://clinicaltrials.gov/study/NCT07160725

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07160725.json